Two New Drugs for Gonorrhea
March 16, 2026 (Issue: 1750)
The FDA has approved two antibiotics, gepotidacin
(Blujepa — GSK) and zoliflodacin (Nuzolvence —
Entasis), for oral treatment of uncomplicated
urogenital gonorrhea in patients ≥12 years old.
Gepotidacin is approved for use in persons...more
- FDA News Release. FDA approves two oral therapies to treat gonorrhea. December 12, 2025. Available at: https://bit.ly/4aSfwsp. Accessed February 26, 2026.
- Gepotidacin (Blujepa) – a new antibiotic for uncomplicated UTI. Med Lett Drugs Ther 2026; 68:1.
- KA Workowski et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021; 70:1. doi:10.15585/mmwr.rr7004a1
- Drugs for sexually transmitted infections. Med Lett Drugs Ther 2026 (in press).
- X Zhu et al. Ceftriaxone-resistant gonorrhea – China, 2022. MMWR Morb Mortal Wkly Rep 2024; 73:255. doi:10.15585/ mmwr.mm7312a2
- N Osheroff. Gyrase and topoisomerase IV as antibacterial targets for gepotidacin and zoliflodacin: teaching old enzymes new tricks. Int J Mol Sci 2026; 27:496. doi:10.1016/s0140-6736(25)00628-2
- MJ Cole et al. In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates. J Antimicrob Chemother 2026; 81:dkag001. doi:10.1093/jac/dkag001
- L Yao et al. In vitro activity of zoliflodacin against Neisseria gonorrhoeae isolates from Shanghai, China (2020-2023).Antibiotics (Basel) 2026; 15:61. doi:10.3390/antibiotics15010061
- JDC Ross et al. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet 2025; 405:1608. doi:10.3390/ijms27010496
- A Luckey et al. Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial. Lancet 2026; 407:147. doi:10.1016/s0140-6736(25)01953-1
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RL Woosley et al. QTdrugs list, AZCERT, Tucson, AZ. Available at: www.crediblemeds.org. Accessed February 26, 2026.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. February 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
